Agomelatine for the Treatment of Patients with Fibromyalgia and Depressive Symptomatology: An Uncontrolled, 12-Week, Pilot Study

Abstract

Introduction:

Agomelatine, a melatonin agonist and selective 5-HT2C antagonist, is a novel antidepressant with sleep-enhancing properties. The purpose of this study was to assess the efficacy and tolerability of agomelatine among patients with fibromyalgia and depression.

Methods:

23 patients with fibromyalgia and depressive symptomatology received 25–50 mg of agomelatine daily for 12 weeks. The primary outcome measure was the change of the Beck depression inventory score. Secondary outcome measures included the hospital anxiety and depression scale, Pittsburgh sleep quality index, Fibromyalgia Impact Questionnaire, short-form health survey, brief pain inventory and patient’s global impression scale.

Results:

Agomelatine significantly improved depression, global fibromyalgia severity and pain intensity but effect sizes were small. No improvement was seen in sleep quality. Patients categorized as responders to treatment had milder disease severity than non-responders. Agomelatine therapy was well tolerated and patients only reported mild and transient side effects.

Discussion:

Agomelatine slightly improved depressive and fibromyalgia symptomatology but did not improve sleep quality. Our data do not support agomelatine as a first-line treatment option for the treatment of fibromyalgia and depression.

Key words

fibromyalgia - depression - agomelatine - sleep quality

• References

• 1 Smith HS, Robert RL. Fibromyalgia syndrome: a discussion of the syndrome and pharmacotherapy. Am J Ther 2010; 17: 418-439
• 2 Pae CU, Luyten P, Marks DM et al. The relationship between fibromyalgia and major depressive disorder: a comprehensive review. Curr Med Res Opin 2008; 24: 2359-2371
• 3 Gracely RH, Ceko M, Bushnell MC. Fibromyalgia and depression. Pain Res Treat 2012; [Epub ahead of print]
• 4 Spaeth M, Rizzi M, Sarzi-Puttini P. Fibromyalgia and sleep. Best Pract Res Clin Rheumatol 2011; 25: 227-239
• 5 Racagni G, Riva MA, Molteni R et al. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. World J Biol Psychiatry 2011; 12: 574-587
• 6 Zupancic M, Guillerminault C. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 2006; 12: 981-992
• 7 Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007; 22: 283-291
• 8 European Medicines Agency. CHMP assessment report for Valdoxan. 2008 Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Public_assessment_report/human/000915/WC500046226.pdf (latest access on 2013 June 24)
• 9 Wikner J, Hirsch U, Wetterberg L et al. Fibromyalgia – a syndrome associated with decreased nocturnal melatonin secretion. Clin Endocrinol (Oxf) 1998; 49: 179-183
• 10 Senel K, Baygutalp F, Baykal T et al. Melatonin levels in premenopausal women with fibromyalgia syndrome. Rheumatol Int 2013; [Epub ahead of print]
• 11 Press J, Phillip M, Neumann LL et al. Normal melatonin levels in patients with fibromyalgia syndrome. J Rheumatol 1998; 25: 551-555
• 12 Klerman EB, Goldenberg DL, Brown EN et al. Circadian rhythms of women with fibromyalgia. J Clin Endocrinol Metab 2001; 86: 1034-1039
• 13 Korszun A, Sackett-Lundeen L, Papadopoulos E et al. Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. J Rheumatol 1999; 26: 2675-2680
• 14 Acuña-Castroviejo D, Escames G, Reiter RJ. Melatonin therapy in fibromyalgia. J Pineal Res 2006; 40: 98-99
• 15 Citera G, Arias MA, Maldonado-Cocco JA et al. The effect of melatonin in patients with fibromyalgia: a pilot study. Clin Rheumatol 2000; 19: 9-13
• 16 Hussain SA, Al-Khalifa II, Jasim NA et al. Adjuvant use of melatonin for treatment of fibromyalgia. J Pineal Res 2011; 50: 267-271
• 17 Wolfe F, Smythe HA, Yunus MB et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 1990; 33: 160-172
• 18 European Medicines Agency. Valdoxan. 2009 Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000915/human_med_001123.jsp&mid=WC0b01ac058001d124 (latest access on 2013 June 24)
• 19 Dworkin RH, Turk DC, Wyrwich KW et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008; 9: 105-121
• 20 Sanz J, Perdigón AL, Vázquez C. Adaptación española del inventario para la depresión de Beck-II (BDI-II): 2. Propiedades psicométricas en población general. Clínica y Salud 2003; 14: 249-280
• 21 Herrero MJ, Blanch J, Peri JM et al. A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population. Gen Hosp Psychiatry 2003; 25: 277-283
• 22 Royuela A, Macías JA. Propiedades clinimétricas de la versión castellana del cuestionario de Pittsburgh. Vigilia-Sueño 1997; 9: 81-94
• 23 Rivera J, González T. The Fibromyalgia Impact Questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol 2004; 22: 554-560
• 24 Vilagut G, Ferrer M, Rajmil L et al. The Spanish version of the Short Form 36 Health Survey: a decade of experience and new developments. Gac Sanit 2005; 19: 135-150
• 25 Badía X, Muriel C, Gracia A et al. Validation of the Spanish version of the Brief Pain Inventory in patients with oncological pain. Med Clin 2003; 120: 52-59
• 26 Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989; 27: S178-S189
• 27 Kräuchi K, Cajochen C, Möri D et al. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol 1997; 272: R1178-R1188
• 28 Quera-Salva MA, Lemoine P, Guilleminault C. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. Hum Psychopharmacol 2010; 25: 222-229
• 29 Bruno A, Micò U, Lorusso S et al. Agomelatine in the treatment of fibromyalgia: a 12-week, open-label, uncontrolled preliminary study. J Clin Psychopharmacol 2013; 33: 507-511
• 30 Häuser W, Bartram-Wunn E, Bartram C et al. Placebo responders in randomized controlled drug trials of fibromyalgia syndrome: Systemic review and meta-analysis. Schmerz 2011; 25: 619-631
• 31 Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Clin Nueropsychopharmacol 2011; [Epub ahead of print]
• 32 Howland RH. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. Neuropsychiatr Dis Treat 2009; 5: 563-576
• 33 Moldofsky H. The significance, assessment, and management of nonrestorative sleep in fibromyalgia syndrome. CNS Spectr 2008; 13: 22-26
• 34 Häuser W, Petzke F, Üçeyler N et al. Comparative efficacy and acceptability of amitriptyline, duloxetine, milnacipran in fibromyalgia syndrome: a systemic review with meta-analysis. Rheumatology (Oxford) 2011; 50: 532-543
• 35 Straube S, Derry S, Moore RA et al. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford) 2010; 49: 706-715
• 36 Morillas-Arques P, Rodriguez-Lopez CM, Molina-Barea R et al. Trazodone for the treatment of fibromyalgia: an open-label, 12 week study. BMC Musculoeskeletal Disord 2010; 11: 204
• 37 Staud R. Sodium oxybate for the treatment of fibromyalgia. Expert Opin Pharmacother 2011; 12: 1789-1798
• 38 Aaron LA, Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med 2001; 134: 868-881
• 39 Pimentel MJ, Gui MS, Martins de Aquino LM et al. Features of temporomandibular disorders in fibromyalgia syndrome. Cranio 2013; 31: 40-45
• 40 Smith MT, Wickwire EM, Grace EG et al. Sleep disorders and their association with laboratory pain sensitivity in temporomandibular joint disorder. Sleep 2009; 32: 779-790
• 41 Ambriz-Tututi M, Rocha-González HI, Cruz SL et al. Melatonin: a hormone that modulates pain. Life Sci 2009; 84: 489-498
• 42 Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol 2006; 21: S31-S35